2011 - CTS-IXA


This page contains exclusive content for the member of the following sections: TTS, CTS, IXA. Log in to view.

SOTA 5- Taking Islet Xenotransplantation to the Clinic (Xeno Track)

24.354 - Islet Quality Assurance - from the farm to the patient regulatory issues in islet xeno

Presenter: Gregory S., Korbutt, Edmonton, Canada
Authors: Gregory S. Korbutt

354

Islet quality assurance – from the farm to the patient regulatory issues in islet xenotransplantation

Gregory S Korbutt

University of Alberta & Alberta Diabetes Institute, Edmonton, Canada

Patients with brittle type 1 diabetes can now be protected from severe hypoglycemia and improved glycemic stability following islet transplantation. However, widespread application of this treatment will necessitate the need to develop an alternative to human donor islets. Studies have reported successful transplantation of porcine islets from fetal, neonatal, and adult porcine pancreases. In addition to studies in rodents, fetal porcine islets have been isolated from pigs of gestational age 60 to 69 days have been transplanted into patients with type 1 diabetes, whereas neonatal and adult porcine islets have been implanted into diabetic non-human primates. Therefore, xenotransplantation of porcine islets isolated from either fetal, neonatal, or adult animals have many strengths and are becoming closer to clinical application. This presentation will provide recommendation for regulatory issues involved in future clinical studies using xenogeneic porcine pancreatic islet cell products for the treatment of type 1 diabetes. Porcine islet product release criteria will also be presented that will be helpful in establishing the safety (endotoxin, sterility), identity/purity (cell composition), quantity (islet equivalents, cell number), vitality (membrane intactness), and potency (insulin secretory capacity) of biological porcine islet cell products.


Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
info@tts.org

Address

The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6
Canada